Artur Jurczyszyn

Krakow, MA, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.

Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.

Journal: Molecular cancer

Published: July 17, 2026

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 16, 2026

Fatty acids profile in plasma of patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).

Fatty acids profile in plasma of patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).

Journal: Folia medica Cracoviensia

Published: December 17, 2025

The influence of chronic hepatitis B virus infection on fatty acid composition in erythrocyte membranes and plasma, and its effect on lipoxin A4 and resolvin D1 levels.

The influence of chronic hepatitis B virus infection on fatty acid composition in erythrocyte membranes and plasma, and its effect on lipoxin A4 and resolvin D1 levels.

Journal: Folia medica Cracoviensia

Published: December 02, 2025

Edmund Biernacki: a forgotten father of clinical hematology.

Edmund Biernacki: a forgotten father of clinical hematology.

Journal: Polish archives of internal medicine

Published: September 29, 2025

New therapies in multiple myeloma: benefits and limitations.

New therapies in multiple myeloma: benefits and limitations.

Journal: Polish archives of internal medicine

Published: April 15, 2025

The Positive Effects of Training and Time-Restricted Eating in Gut Microbiota Biodiversity in Patients with Multiple Myeloma.

The Positive Effects of Training and Time-Restricted Eating in Gut Microbiota Biodiversity in Patients with Multiple Myeloma.

Journal: Nutrients

Published: November 17, 2024

The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma.

The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma.

Journal: Current oncology (Toronto, Ont.)

Published: November 06, 2024

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)

Published: September 17, 2024

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

Journal: European journal of haematology

Published: August 24, 2024

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.

Journal: EJHaem

Published: June 06, 2024

Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.

Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.

Journal: Cancers

Published: March 17, 2024

Showing 1-12 of 172

Last Updated: 09/26/2026